Home Featured 2

Featured 2

Featured posts

Random

Global Survey for Pathologists on PD-L1 Testing: Moving Toward Standardization

lungcanc

Nuances of PET Interpretation in Thoracic Oncology: More Than Just Lung Cancer

ICU Care for the Patient with Lung Cancer

The IASLC Pathology Committee Recommendations for the Use of Diagnostic Immunohistochemistry in Lung Cancer

PACIFIC Flooded Us with Optimism. Now What?

TTFields in Mesothelioma (The STELLAR Trial): More Stars Needed in the...

lungcanc

Liquid Biopsy’s Role in Marker Identification: An Interview With Dr. Martin...

lungcanc

Treating Patients with MET Alterations: A Q&A with Dr. Ravi Salgia

lungcanc

The Changing the Landscape of Tobacco Products: Potential Effects of ENDS...

lungcanc

Adjuvant EGFR-TKI for Resected NSCLC: Who, When, and Where?

lungcanc

Diagnostic Oncology: Reports from the IASLC Pathology Committee

lungcanc

PD-L1 in Cytology Specimens

lungcanc

Dr. Richard Pazdur Discusses Project Facilitate and the Expanded-Access Program

lungcanc

Journal Radar: Robust Survival Duration Shown in NSCLC With Pembrolizumab

lungcanc

Stage IIIA NSCLC: A Review of Recent and Ongoing Trials Trial

lungcanc

12 3...7 Page 1 of 7

Meeting News

Leora Horn, MD – IASLC Virtual Presidential Symposium Presentation

Paul Baas, MD – IASLC Virtual Presidential Symposium Presentation

TRACERx Data Show That Tracking MRD With ctDNA Heralds Disease Relapse

cfDNA Analysis Suggests EML4-ALK Variant Does Not Influence Response to Lorlatinib